Science

WHO hails ‘good news’ about two Covid-19 vaccine candidates

Hemani Sheth Mumbai | Updated on July 21, 2020 Published on July 21, 2020

A representative image   -  Reuters

The World Health Organization on Monday hailed the “good news” of positive results from two Covid-19 vaccines that have proven safe for humans and have produced a positive immune response against the infection.

“It is good news,” Dr Michael Ryan, head of emergencies at the WHO, told a press briefing.

“We have 23 Covid-19 candidate vaccines in clinical development and as of today we have one candidate vaccine for which Phase I clinical data was available,” he said.

“It is great to see data coming through into peer-reviewed journals,” he added.

The statement comes in the light of two different studies published in Lancet.

The journal on Monday published Phase I results from AstraZeneca’s vaccine candidate developed in collaboration with Oxford University that had shown positive immune response. The trials consisted of 1,000 healthy volunteers.

In a second study, a Covid-19 vaccine candidate from China’s CanSino Biologics had also shown positive immune response for candidates in clinical trials.

“Both vaccine doses induced significant neutralising antibody responses to live SARS-CoV-2, with GMT of 19.5 & 18.3 in participants receiving high & low dose, respectively. Binding antibody response peaked at 656.5 & 571 ELISA units for high & low vaccine dose, respectively,” Lancet had tweeted.

Ryan emphasised the need for further trials on a larger scale to determine the efficacy of the vaccines.

“We now need to move into larger-scale real-world trials. But it is good to see more data and more products moving into this very important phase of vaccine discovery,” Ryan said.

Chinese researchers from CanSino Biologics published a study on their experimental vaccine,

Other front-runners of the vaccine race include US firm Moderna’s experimental vaccine, which will begin the next phase of trials on July 27. Meanwhile, a vaccine candidate under development by Pfizer Inc and Germany's BioNTech has also shown promise in early studies.

AstraZeneca will also be conducting a clinical study in India for its “promising” Covid-19 vaccine candidate.

“We will be doing a study in India. It’s a big country and there is a lot of infection,” AstraZeneca Chief Executive Pascal Soriot told BusinessLine.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on July 21, 2020
WHO
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.
Richcore LifeSciences to expand its recombinant protein manufacturing capability